Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 54

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 16
Chunk 54
---
, 2024.

        Options

        Weighted-AverageExercise PricePer Share

        Weighted-AverageRemaining Contractual Term

        Aggregate Intrinsic Value(in thousands)

        Outstanding at December 31, 2023

        10,211,758

        $
        17.10

        Granted

        2,915,362

        $
        14.28

        Exercised

        (172,163
        )
         
        $
        13.18

        $
        401.5

        Forfeiture

        (827,522
        )
         
        $
        16.84

        Outstanding at December 31, 2024

        12,127,435

        $
        16.50

        7.5

        $
        748.5

        Vested and expected to vest at December 31, 2024

        12,127,435

        $
        16.50

        7.5

        $
        748.5

        Exercisable at December 31, 2024

        7,610,570

        $
        16.66

        7.0

        $
        431.2

      Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of options exercised during the years ended December 31, 2024, 2023, and 2022 was $0.4 million, $0.6 million and $1.6 million, respectively.The total fair value of options that vested during the years ended December 31, 2024, 2023, and 2022 were $33.3 million, $29.2 million and $23.1 million, respectively. The weighted-average grant date fair value of options granted during the years ended December 31, 2024, 2023, and 2022 were $9.22 per share, $13.14 per share, and $10.03 per share, respectively. Unrecognized share-based compensation for stock options as of December 31, 2024 was $45.9 million, which is expected to be recognized over a weighted-average period of 2.1 years.
The Company used the Black-Scholes option pricing model to estimate the fair value of stock option awards granted with the following